Biotechs on edge as money evaporates
Seattle’s biotech industry is working on some of the most complicated medical science in the world, but it relies on a simple mantra its executives know by heart: “Cash is king.”
Making a Run for the Border-For Canadian Prescription Drugs
Picture a tour bus filled with American seniors heading for a visit north of the border, to Canada. Instead of paying a visit to the Canadian side of Niagara Falls, they are off to purchase Canadian prescription drugs. As strange as this sight may seem, this is [...]
Biotech industry seeks control of its destiny
Human Genome Sciences and a small but determined group of its peers are charting unconventional territory. Their efforts to take over the production, sales and marketing of selected portions of their portfolios signals a potential turning point in the industry. The companies contend that they can and should own [...]
Singapore’s biotech bid
Singapore is rolling out the red carpet to foreign scientists and entrepreneurs in an ambitious bid to build up its biotech sector. The government has set aside $2 billion for research in biotech, health care and medical technology until 2005, and pledged $285 million for science scholarships.
Big Pharma: Getting Too Big for Its Own Good?
A study by McKinsey & Co. earlier this year looked at the net present value of products out of research vs. the spending on R&D for the top pharma players over the last decade. It found no correlation between the return on investment and a company’s size
European Patent Office bars human cloning in patent
The European Patent Office added restrictions on Wednesday to a controversial patent granted in 1999 to prevent it being used to clone humans, a ruling limiting biotech research in Europe.